liposomal irinotecan

Ipsen, Servier announce initial phase 1/2 data of liposomal irinotecan in metastatic pancreatic cancer
Pharmaceutical Business Review
Mon, 07/8/19 - 10:25 am
Ipsen
Servier
liposomal irinotecan
pancreatic cancer